Europe – Vaccine against COVID-19: Council adopts measures to facilitate swift development

Today, the Council adopted a regulation which aims to speed up the development and the deployment of a vaccine against COVID-19 in the EU. The act provides for a temporary derogation for clinical trials with such vaccines from the prior environmental risk assessment required in the EU legislation on the deliberate release in the environment and the contained use of genetically modified organisms (GMOs). In addition, it clarifies that this temporary derogation also applies when member states allow medicinal products containing or consisting of GMOs intended to treat or prevent COVID-19 to be used in certain exceptional and urgent situations defined in the pharmaceuticals legislation. The environmental impact of medicinal products (including vaccines) containing or consisting of GMOs intended to treat or prevent COVID-19 will remain part of the marketing authorisation process, respecting the environmental safety requirements set out in the GMO legislation.

The regulation will apply only as long as COVID-19 is regarded as a pandemic by the World Health Organisation (WHO) or as long as an implementing act by which the Commission recognises a situation of public health emergency due to COVID-19 applies.

A vaccine against COVID-19 is urgently needed. This regulation will ensure that clinical trials in the EU can start without delay and that no precious time is lost. The act adopted today shows that the EU is ready to take the lead in the global effort to secure the development of a safe and efficient vaccine…